energizing
drug discovery in
neurodegenerative diseases
scroll arrow
people image
About us

NRG Therapeutics is passionate about bringing new medicines and hope to the growing number of people worldwide living with debilitating neurodegenerative disorders.

A neuroscience-focussed drug discovery company building a pipeline of disease modifying drug candidates, NRG Therapeutics is focused on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s and Amyotrophic Lateral Sclerosis, ALS (also known as motor neurone disease, MND).

scroll arrow
Science

NRG Therapeutics is leveraging breakthrough science in the field of mitochondrial biology to identify new therapeutic targets to treat neurodegenerative disorders.

The company is advancing a pipeline of potential first-in-class, brain-penetrant, oral small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with the aim of restoring mitochondrial function and slowing or halting the progression of Parkinson’s and ALS, also known as motor neurone disease (MND). 

scroll arrow
Latest news
Oct 31, 2024
NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases
Sep 5, 2024
NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND
Proud members of